Amarin shares fall 10% as patent wrangling continues, but analysts remain confident
This article was originally published in Scrip
Shares in Irish biotech Amarin fell nearly 10% on 2 March, as the US Patent and Trademark Office (PTO) issued yet another non-final rejection for one of Amarin's 16 patent applications. The company filed a note with the SEC highlighting its continuing struggle to gain use patents for its lead candidate AMR101, which it has filed in the US as a treatment for patients with very high triglycerides.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.